Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of SULGEN Spray Birke in birch pollen allergy
2011-002319-27Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Jun 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of birch pollen allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and birch pollen allergy (5 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Percentage of patients with any improvement in titrated nasal provocation test response. Started Jun 2020; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)birch pollen allergy
Beyond the preview
Go deeper on 2011-002319-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002319-27.